Background: Multiple antibiotic-resistant clones of Streptococcus pneumoniae have spread throughout the world and continue to evolve under the selective pressure of antibiotics and vaccines. The aim of this study is to assess the susceptibility of S. pneumoniae isolates and to analyze the resistance trends in Taiwan. Methods: Antimicrobial susceptibility tests were performed on 152 nonmeningeal isolates of S. pneumoniae that were collected from 13 different hospitals around Taiwan from 2006e 2007. Tests were performed using the broth microdilution method according to recommendations of the Clinical and Laboratory Standards Institute. Results: The minimal inhibitory concentrations (MIC 50 /MIC 90 ) of penicillin, cefotaxime, vancomycin, and moxifloxacin were 0.5/1.0, 0.25/1.0, 0.25/0.5, and 0.06/0.12 mg/mL, respectively. The susceptibility rates of penicillin, cefotaxime, vancomycin, and moxifloxacin were 99.3%, 99.3%, 100%, and 98.7%, respectively. However, if the meningitis breakpoints were applied to these nonmeningeal isolates, the susceptibility rates of penicillin and cefotaxime were reduced to 18.4% and 76.3%, respectively. Compared with the findings from previous studies in Taiwan, our results show that the percentage of S. pneumoniae isolates with a penicillin MIC of 0.12 e1.0 mg/mL increased from 43.3% in 1996 e1997 to 73.7% in 2006 e2007 (p < 0.001). The percentage of S. pneumoniae isolates with a cefotaxime MIC of 1.0 mg/mL increased from 11.3% in 1996e1997 to 23.0% in 2006e2007 (p < 0.001). Regarding the serial MIC intervals of the four antimicrobial agents, there was no significant difference between bacteremic and nonbacteremic isolates. Conclusion: Although nonmeningeal S. pneumoniae isolates remained susceptible to penicillin, the proportion of isolates with a penicillin MIC of 0.12e1.0 mg/mL or cefotaxime MIC of 1.0 mg/mL increased during the past decade in Taiwan. The ever-increasing resistance of S. pneumoniae has a great impact on the treatment of meningitis.
Introduction
Penicillin-resistant Streptococcus pneumoniae (PRSP) was first reported in the late 1960s. 1 Subsequently, S. pneumoniae isolates with a higher levels of penicillin and multidrug-resistance (MDR) were found in South Africa in the late 1970s. 2 Higher prevalence rates of PRSP were reported in Europe and the USA in the 1990s. 3 The overall resistance to penicillin (minimal inhibitory concentrations [MIC] ! 2.0 mg/mL) was 23% (range: 6e54%), with the highest prevalence found in Spain and France (> 50%). 3 A report from the SENTRY Antimicrobial Surveillance Program (1999e2003) showed that the incidence of penicillin resistance (MIC ! 2.0 mg/mL) in S. pneumoniae was 14.7% in Europe, 12.7% in Latin America, and 15.9% in North America. 4 In North America, the prevalence of MDR S. pneumoniae increased from 5.7% in 1999 to 6.3% in 2003. 4 Clones of MDR S. pneumoniae have now been discovered worldwide. 5e7 The application of the new nonmeningeal breakpoints of penicillin (by CLSI-M100-S18 in 2008) had a great impact on susceptibility rates. Data from the SENTRY Antimicrobial Surveillance Program in 2006 were assessed using these new breakpoints. 8 Using a penicillin susceptibility breakpoint of 0.06 mg/mL, only 68% of isolates are susceptible to penicillin; in contrast, using a breakpoint of 2.0 mg/mL, 93% of isolates are susceptible. 8 The prevalence of penicillin-insusceptible S. pneumoniae has been reported in Taiwan, with rates ranging from 56.4% (43% isolates with MIC of 0.12e1.0 mg/mL and 13.1% with MIC ! 2.0 mg/mL) in the late 1990s and 76.2% (50.7% with MIC of 0.12e1.0 mg/mL and 25.5% with MIC ! 2.0 mg/mL) in the early 2000s.
9e11 International clones of MDR S. pneumoniae have been identified in Taiwan since 1998. 12 The resistance patterns of S. pneumoniae continue to evolve under the selective pressure of multiple factors (such as the use of antimicrobial agents, 13 clonal spread among hosts, 7 and vaccination). 14, 15 The aim of this study is to assess the susceptibility of S. pneumoniae isolates, analyze resistance trends in Taiwan, and discuss the impact of revised nonmeningeal breakpoints recommended by the CLSI M100-S18.
Methods

S. pneumoniae isolates
One hundred and fifty-two unique isolates of S. pneumoniae were collected from 13 different hospitals in Taiwan 
Broth microdilution
Antimicrobial susceptibility was assessed by broth microdilution according to the standard method approved by the CLSI. 16 The bacterial isolates were incubated overnight on 5% sheep blood agar plates. Inoculants were prepared from the bacterial colonies that formed on the 5% sheep blood agar plates, and then the colonies were suspended in 0.9% saline with a turbidity equivalent of 0.5 McFarland units. The suspension was further diluted within 15 minutes to give a final inoculum density of 5 Â 10 5 CFU/mL in each test tube, containing 1.0 mL of antimicrobial agent that had been diluted in Mueller-Hinton broth with 5% lysed sheep blood. The following concentrations of penicillin and cefotaxime were used: 4 mg/mL, 2 mg/mL, 1 mg/mL, 0.5 mg/mL, 0.25 mg/mL, 0.12 mg/mL, 0.06 mg/mL, 0.03 mg/ mL, and 0.01 mg/mL. The test tubes were incubated at 35 C in ambient air for 20e24 hours prior to determining MIC. S. pneumoniae ATCC 49619 was used as the control strain. The CLSI interpretive criteria 17 for MICs are as follow: (1) 
Statistical analysis
Analyses were performed by using the Statistical Package for the Social Science (version 15.1; SPSS Inc, Chicago, IL, USA) & SAS 9.1.3. The Kendall's tau-c test was used for comparisons of trends in the susceptibilities of S. pneumoniae isolates in Taiwan from 1996 to 2007, and the Pearson's chi-squared test was used for comparisons of the susceptibilities of 42 bacteremic and 110 nonbacteremic S. pneumoniae isolates. A difference was considered statistically significant if the two-tailed p-value <0.05.
Results
Susceptibility
The susceptibilities of the 152 S. pneumoniae isolates are shown in Table 1 . The MIC 50 and MIC 90 of penicillin, cefotaxime, vancomycin, and moxifloxacin were 0.5/1.0, 0.25/ 1.0, 0.25/0.5, and 0.06/0.12 mg/mL, respectively. The susceptibility rates of penicillin, cefotaxime, vancomycin, and moxifloxacin were 99.3%, 99.3%, 100%, and 98.7%, respectively.
Comparisons of the susceptibilities of the 152 S pneumonia isolates using nonmeningeal and meningeal breakpoint criteria are shown in Table 1 . According to the meningeal breakpoint, the susceptibility rates of penicillin and cefotaxime were 18.4% and 76.3%, respectively, while the resistance rates were 81.6% and 0.7%, respectively.
Cross-resistance between penicillin and cefotaxime
The cross-susceptibility and cross-resistance of penicillin and cefotaxime were analyzed and the results are listed in Table 2 . The data generally show good categorical agreement between the MICs of penicillin and cefotaxime. However, there are some disagreements. For example, there were 8 isolates with penicillin MICs between 0.12e1.0 mg/mL, but the cefotaxime MICs 0.06 mg/mL; 10 isolates with penicillin MIC ! 2.0 mg/mL were identified, but their cefotaxime MICs were in the range of 0.12e1.0 mg/mL.
Trends in susceptibility
The susceptibility rates of the isolates in this study were assessed and compared with the results of two previous studies that were conducted in Taiwan. 9, 18 Table 3 lists the changes in the susceptibility trends of S. pneumoniae isolates in Taiwan from 1996e2007. The serial percentages of S. pneumoniae isolates with penicillin MIC of 0.12e1.0 mg/mL were 43.3%, 38.7%, and 73.7%, respectively, whereas the serial percentages of S. pneumoniae isolates with penicillin MIC ! 2.0 mg/mL were 13.1%, 44.5%, and 7.9%, respectively. The percentage of S. pneumoniae isolates with penicillin MIC of 0.12e1.0 mg/mL increased from 43.3% in 1996e1997 to 73.7% in 2006e2007 (p < 0.001). The serial percentages of S. pneumoniae isolates with cefotaxime MIC of 1.0 mg/mL were 11.3%, 34.6 %, and 23.0%, respectively, while the serial percentages of S. pneumoniae isolates with cefotaxime MIC ! 2.0 mg/mL were 2.2%, 6.9%, and 0.7%, respectively. The percentage of S. pneumoniae isolates with cefotaxime MIC of 1 mg/mL increased from 11.3% in 1996e1997 to 23.0% in 2006e2007 (p < 0.001).
Comparisons of the susceptibilities of bacteremic and nonbacteremic isolates
Comparisons of the susceptibilities of 42 bacteremic and 110 nonbacteremic S pneumonia isolates are shown in Table 4 . The susceptibilities of these isolates did not differ significantly (p Z 0.798, 1, and 1 for penicillin, cefotaxime, and moxifloxacin, respectively).
Discussion
Of the 152 isolates, only 1 isolate (0.7%) was resistant to penicillin with an MIC of 4.0 mg/mL and only 1 isolate (0.7%) was resistant to cefotaxime with an MIC of 4.0 mg/mL. S. pneumoniae isolates with high resistance levels to extended-spectrum cephalosporins have been reported in the USA, the UK, Spain, and New Zealand since 1995. Extended-spectrum cephalosporin-resistant S. pneumoniae isolates from the USA appear to have emerged from different clones. 19 A multidrug-resistant 19F clone of S. pneumoniae with high-level cefotaxime resistance was identified in New Zealand in 1997e1998. 22 S. pneumoniae isolates with high-level resistance to cephalosporin (1.4% of 364 isolates) were also reported in another Taiwanese study in 2008. 18 The genotypes of S. pneumoniae isolates with high-level b-lactam resistance (penicillin MIC ! 4.0 mg/mL and cefotaxime ! 2.0 mg/mL) were then analyzed by multilocus sequence typing, 18 and three clones (Spain 23F -1, Taiwan 19F -14, and Taiwan 23F -15) were identified. Determining the susceptibility breakpoint depends on the desired microbiological, pharmacokinetic, and/or pharmacodynamic clinical outcomes. 8 An intravenously administered 2 MU dose of penicillin every 4 hours would have a 99% likelihood of achieving serum concentrations greater than the MIC of 25% of the therapy interval when treating an isolate with an MIC of 2.0 mg/mL. 23 A metaanalysis suggested that increased mortality is not associated with an penicillin MIC ! 2.0 mg/mL for pneumococcal pneumonia. 24 These data support a penicillin-susceptible breakpoint 2.0 mg/mL for nonmeningeal isolates. 17 In this study, if the susceptibilities of all of the 152 nonmeningeal isolates were interpreted with the former penicillin-susceptible breakpoint 0.06 mg/mL, 25 only 18.4% of isolates would be susceptible to penicillin. In contrast, using the revised penicillin-susceptible breakpoint 2.0 mg/mL, 99.3% of isolates would be susceptible to penicillin. Using this revised nonmeningeal breakpoint of penicillin, the proportion of isolates susceptible to penicillin would be comparable with the proportion of isolates susceptible to the nonmeningeal breakpoint of cefotaxime (99.3%). In the USA from 2005e2006, the three surveillance networks (SENTRY, PROTEKT, and ABCs surveillance) reported that the susceptibility increased by approximately 25%, using the revised penicillin-susceptible breakpoint 2.0 mg/mL for nonmeningeal infections. 8 The susceptibility of these nonmeningeal S. pneumoniae isolates remained high enough for the treatment of nonmeningeal infections. S. pneumoniae, though isolated from nonmeningeal sources, is also a potential pathogen of Table 2 Cross-susceptibility and cross-resistance analyses of the MIC intervals of penicillin compared with the MIC intervals of cefotaxime for 152 S. meningitis. If the revised CLSI breakpoints for meningitis are applied to these nonmeningeal isolates, there will be a very dramatic impact on the susceptibility of S. pneumoniae to penicillin and cefotaxime. Resistance rates will be much higher if meningeal breakpoints are applied to these nonmeningeal isolates. The following results are likely: only 18.4% of isolates will be susceptible to penicillin and 76.3% will be susceptible, 23% will be intermediately susceptible, and 0.7% will be resistant to cefotaxime. Categorical disagreement between the MICs of penicillin and cefotaxime was found in 22 isolates. This could be explained by alterations in penicillin-binding proteins that could result in different binding affinities for different b-lactams, e.g., penicillin and cefotaxime. 26 Although 99.3% of the isolates were susceptible to penicillin using the nonmeningeal breakpoint, the percentage of S. pneumoniae isolates with penicillin MIC of 0.12e1.0 mg/mL increased from 43.3% (during the period of 1996e1997) to 73.7% (during the period of 2006e2007) (p < 0.001). The percentage of S. pneumoniae isolates with penicillin MIC of 2.0 mg/mL decreased from 13.1% (during the period of 1996e1997) to 7.9% (during the period of 2006e2007) (p < 0.001). Interpreting susceptibility by looking at just susceptibility or resistance will often mask changes in the MIC distribution and changes in resistance trends. Monitoring detailed MIC data is important for epidemiology studies and determining appropriate treatment strategies.
Regarding the serial MIC intervals of the four antimicrobial agents, there were no significant differences between bacteremic and nonbacteremic isolates. Only some major clones of antibiotic-resistant S. pneumoniae were found to be spreading in Taiwan; for example, Taiwan-23F, Taiwan-19F, Spanish-23F, Spanish-6B, Spanish-9 V, ST320 (19A), and ST902 (6A). 12, 27 The most prevalent serotypes of invasive isolates also were attributed to these serotypes. 10, 27 Therefore, the diversity of resistance patterns is limited.
In conclusion, although nonmeningeal S. pneumoniae isolates remain susceptible to penicillin, the proportion of isolates with a penicillin MIC of 0.12e1.0 mg/mL or cefotaxime MIC of 1.0 mg/mL has increased during the past decade in Taiwan. The ever-increasing resistance of S. pneumoniae has a great impact on the treatment of meningitis. 
